{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-049060","form_type":"8-K","ticker":"IOVA","cik":"0001425205","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","filed_at":"2023-04-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.810566+00:00","generated_at":"2026-06-16T18:44:49.647545+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Iovance appoints Wendy L. Yarno to Board; Wendy L. Dixon not standing for re-election","bullets":["Wendy L. Yarno appointed as director effective April 18, 2023; previously EVP & CMO at Merck over 26 years.","Wendy L. Dixon will not stand for re-election at June 2023 annual meeting; will serve until meeting ends.","Board increased from 7 to 8 members for Yarno's seat; will reduce back to 7 after annual meeting.","Yarno granted standard deferred restricted stock unit per new-director compensation; no related-party transactions."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-049060","json":"https://secwatch.observer/filing/0001104659-23-049060.json","markdown":"https://secwatch.observer/filing/0001104659-23-049060.md","text":"https://secwatch.observer/filing/0001104659-23-049060.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1425205/000110465923049060/0001104659-23-049060-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1425205/000110465923049060/tm2313552d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T18:44:49.647545+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a989e823c5","claim":"Wendy L. Dixon departed as director at IOVANCE BIOTHERAPEUTICS, INC..","evidence_excerpt":"Wendy L. Dixon, a member of the Board, will not be standing for re-election to the Board at the Company’s annual meeting of stockholders currently anticipated to be held in June 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1425205/000110465923049060/0001104659-23-049060-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will not be standing for re-election"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"b0adb16ceb","claim":"Wendy L. Yarno was appointed as director at IOVANCE BIOTHERAPEUTICS, INC..","evidence_excerpt":"appointed Wendy L. Yarno as a director and new member of the Board, effective April 18, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1425205/000110465923049060/0001104659-23-049060-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}